Molecular imaging in tumor proliferation and angiogenesis: Development of a early assessment tool for measuring the tumor response to treatment with molecular targeted drugs
Project/Area Number |
23591742
|
Research Category |
Grant-in-Aid for Scientific Research (C)
|
Allocation Type | Multi-year Fund |
Section | 一般 |
Research Field |
Radiation science
|
Research Institution | Hokkaido University |
Principal Investigator |
ZHAO SONGJI 北海道大学, 医学(系)研究科(研究院), 教授 (80374239)
|
Co-Investigator(Kenkyū-buntansha) |
NISHIJIMA Kenichi 北海道大学, 大学院医学研究科, 特任講師 (60364254)
TAKEI Toshiki 北海道大学, 大学院医学研究科, 助教 (60374493)
SHIGA Tohru 北海道大学, 大学院医学研究科, 准教授 (80374495)
|
Co-Investigator(Renkei-kenkyūsha) |
KUGE Yuji 北海道大学, アイソトープ総合センター, 教授 (70321958)
|
Project Period (FY) |
2011 – 2013
|
Project Status |
Completed (Fiscal Year 2013)
|
Budget Amount *help |
¥5,200,000 (Direct Cost: ¥4,000,000、Indirect Cost: ¥1,200,000)
Fiscal Year 2013: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2011: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
Keywords | がん分子イメージング / がんの分子標的療法 / 細胞増殖 / 血管新生 / PET/CT / SPECT/CT / PET / SPECT |
Research Abstract |
An early and accurate identification of the tumor response to therapy with molecular targeted drugs is indispensable for selecting optimal personalized treatment strategies. Thus, in this study we utilized molecular imaging technologies including PET and SPECT for visualizing tumor proliferation and angiogenesis/hypoxia, and demonstrated their usefulness in determining the tumor response to molecular targeted drugs at an earlier time stage using animal models. We also demonstrated the potential of our novel candidate compound for angiogenesis imaging in in vitro and in vivo studies. The present results could provide important evidence that may lead to the development of a novel diagnostic and assessment tool for measuring the tumor response to treatment with molecular targeted drugs, taking advantage of molecular imaging technologies for visualizing changes in tumor pathological states at the molecular and cellular levels.
|
Report
(4 results)
Research Products
(42 results)
-
-
-
-
-
[Journal Article] Reoxygenation-induced nitric oxide mitigates tumor hypoxia and radioresistance in a murine SCCVII tumor model2013
Author(s)
Nagane M, Yasui H, Yamamori T, Zhao S, Kuge Y, Tamaki N, Kameya H, Nakamura H, Fujii H, Hirata H, Inanami O
-
Journal Title
Biochem Biophys Res Commun
Volume: 437
Issue: 3
Pages: 420-425
DOI
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
[Presentation] Preparation and evaluation of [^<123>I]IIMU for SPECT imaging of thymidine phosphorylase expression in tumors2013
Author(s)
Nishijima K, Zhao S, Zhao Y, Feng F, Shimizu Y, Abo N, Akizawa H, Ohkura K, Tamaki N, Kuge Y
Organizer
The 20^<th> International Symposium on Radiopharmaceutical Sciences
Place of Presentation
Jeju, Korea
Related Report
-
-
-
-
-
-
-
[Presentation] Preparation and evaluation of [123I]IIMU for SPECT imaging of thymidine phosphorylase expression in tumors2013
Author(s)
Nishijima K, Zhao S, Zhao Y, Feng F, Shimizu Y, Abo N, Akizawa H, Ohkura K, Tamaki N, Kuge Y
Organizer
The 20th International Symposium on Radiopharmaceutical Sciences
Place of Presentation
Jeju International Convention Center (Jeju, Korea)
Related Report
-
-
-
-
-
-
-
-
-
-
[Presentation] FMISO PET reflects antiangiogenic tumor response to multi-kinase inhibitor (sorafenib) in human renal cell carcinoma xenograft2012
Author(s)
Murakami M, Zhao S, Zhao Y, Nusrat C, Yu W, Nishijima K, Takiguchi T, Tamaki N, Kuge Y
Organizer
The 59th Annual Meeting, Society of Nuclear Medicine
Place of Presentation
the Miami Beach Convention Center (Miami, US)
Related Report
-
-
-
-
-
-
-
-
[Presentation] FMISO PET can early evaluate antiangiogenic response to anti-EGFR molecular-targeting therapy (cetuximab) in human lung cancer xenograft.2011
Author(s)
Zhao S, Kuge Y, Zhao Y, Takeuchi S, Murakami M, Li H, Nusrat F Chouwdhury, Nishijima K, Dosaka-Akita H, Tamaki N.
Organizer
The 58th Annual Meeting, Society of Nuclear Medicine
Place of Presentation
The H.B. Gonzalez Convention Center (USA)
Related Report
-
-